Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.
Juan Luis Gomez MartiAzadeh NasrazadaniYing DingDaniel NormolleAdam M BrufskyPublished in: The oncologist (2023)
A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.